Safety of a cytomegalovirus-specific hyperimmunoglobulin in the prevention of maternal–fetal transmission after primary infection—results of an open-label, single-arm, prospective trial
Despite a favorable safety profile, the benefit of treatment with CMVIG to prevent a maternal-fetal CMV transmission could not be demonstrated in our trial.
Authors
- Michael Schneider (ORCID: https://orcid.org/0000-0002-7583-307X)
- M Enders
- Florian Faschingbauer
- Annegret Geipel (ORCID: https://orcid.org/0000-0001-8602-8925)
- Christiane Staiger (ORCID: https://orcid.org/0000-0001-8687-7687)
- Karl Oliver Kagan (ORCID: https://orcid.org/0000-0003-1497-5143)
- Michael Robert Jaskolski (ORCID: https://orcid.org/0000-0002-2375-3916)
- Stephan Lentze
- Joachim Schütze
- Irena Rohr
- Jan-Peter Siedentopf (ORCID: https://orcid.org/0000-0002-8820-0116)
- Julia Jückstöck
- Dimitar Emilov Gechev
- Silke Aigner
Institutions
- University of Applied Sciences Landshut (DE)
- University Hospital Bonn (DE)
- Bayreuth Medical Center (DE)
- Universitätsklinikum Erlangen (DE)
- Institut für Frauengesundheit (DE)
- Universitätsklinik für Frauenheilkunde und Geburtshilfe (AT)
- Biotest (Germany) (DE)
- Medizinisches Versorgungszentrum Prof. Mathey, Prof. Schofer (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Archives of Gynecology and Obstetrics
- Published
- 2026-01-09
- DOI
- https://doi.org/10.1007/s00404-026-08311-8
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00